Compare ADMA Biologics Inc (ADMA) vs Crocs, Inc. (CROX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Crocs, Inc. — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Crocs, Inc. trades at $120.2 (market cap $6.19B). The key difference: Crocs, Inc. is far larger — about 2.9× ADMA Biologics Inc's market cap, and Crocs, Inc. is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | CROX | |
|---|---|---|
Market Cap | $2.13B | $6.19B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $127.77 |
52-Week Low | $7.60 | $73.39 |
Enterprise Value | $2.20B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Crocs (CROX) trades at $124.55, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $4.04B for 2025 but posted a net loss of $81.20M, with negative profit margins. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a 51.35% buy rating and consensus price target of $131.75. News highlights include marketing initiatives like TikTok microdramas and expansion in Asian markets.
The outlook for CROX is mixed: strong brand momentum and earnings beats support upside potential, but profitability concerns and negative net income margins pose risks. Investors should weigh growth initiatives against margin pressures and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
